Zentalis : Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 inhibitor for advanced solid tumors, ZN-d5, a BCL-2 inhibitor for hematologic malignancies and related disorders and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies. Multiple mono and combo trials are ongoing/planned across the pipeline.
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
1B +
1359 Broadway
Suite 1710
New York, NY 12065
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Adam Levy, Senior Vice President of Investor Relations
  • Kim Blackwell, Dr., Chief Executive Officer
  • Melissa Epperly, Chief Financial Officer

Lead Programs

ZN-c3: WEE1i

Potentially first- and best-in class oral inhibitor

Indication Phase
Monotherapy & Combination studies (Multiple) 1/2

ZN-d5: BCL-2

Oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication Phase
Hematologic Malignancies and related disorders 1/2

BCL-xL Degrader

Solid Tumors and Hematologic Malignancies

Indication Phase
Solid Tumors and Heme Malignancies Pre-clinical

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Matrix Capital Management Co. LP 16.12 9,199,973 173.24 13F 12/31/22
Fidelity Management & Research Co. LLC 11.58 6,607,768 124.42 13F 12/31/22
Avidity Partners Management LP 9.02 5,150,000 96.97 13F 12/31/22
The Vanguard Group, Inc. 7.22 4,119,537 77.57 Funds 2/28/23
Vanguard Group, Inc. (Subfiler) 7.08 4,039,096 76.06 13F 12/31/22
Wellington Management Co. LLP 6.34 3,618,493 68.14 13F 12/31/22
State Street Corp. 5.40 3,084,137 58.07 13F 12/31/22
Capital Research & Management Co. (International Investors) 5.34 3,048,182 57.40 13F 12/31/22
Tybourne Capital Management (HK) Ltd. 3.91 2,231,427 42.02 13F 12/31/22
T. Rowe Price Investment Management, Inc. 3.87 2,210,442 41.62 13F 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.